Palatin Technologies
PTNPalatin Technologies is pioneering a novel approach to treating inflammatory and autoimmune conditions by harnessing the body's natural melanocortin system to resolve inflammation and promote tissue healing. The company has advanced clinical programs in dry eye disease and uveitis, a strategic collaboration with Boehringer Ingelheim in retinal diseases, and a marketed product, Vyleesi. With a focus on ocular conditions and metabolic disorders, Palatin aims to address significant unmet medical needs where current anti-inflammatory therapies are limited by safety and efficacy concerns.
PTN · Stock Price
Historical price data
AI Company Overview
Palatin Technologies is pioneering a novel approach to treating inflammatory and autoimmune conditions by harnessing the body's natural melanocortin system to resolve inflammation and promote tissue healing. The company has advanced clinical programs in dry eye disease and uveitis, a strategic collaboration with Boehringer Ingelheim in retinal diseases, and a marketed product, Vyleesi. With a focus on ocular conditions and metabolic disorders, Palatin aims to address significant unmet medical needs where current anti-inflammatory therapies are limited by safety and efficacy concerns.
Technology Platform
Proprietary platform focused on designing selective agonists for the melanocortin receptor system (MC1R-MC5R) to resolve harmful inflammation and modulate immune responses, offering a novel approach distinct from broad immunosuppression.
Pipeline
11| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Bremelanotide + Placebo | Hypoactive Sexual Desire Disorder | Phase 3 | |
| Vehicle Ophthalmic Solution + PL9643 Ophthalmic Solution | Dry Eye | Phase 3 | |
| Bremelanotide | Hypoactive Sexual Desire Disorder | Phase 3 | |
| PL8177 Placebo + PL8177 | Ulcerative Colitis | Phase 2 | |
| Bremelanotide + RAAS inhibition therapy | Kidney Disease | Phase 2 |
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Faces established competitors in dry eye (Allergan/AbbVie, Novartis, Bausch + Lomb), uveitis (AbbVie), and obesity (Novo Nordisk, Eli Lilly). Palatin's differentiation lies in its targeted melanocortin platform, which aims to resolve inflammation rather than broadly suppress it, potentially offering better safety and tolerability profiles.